Memantine Hcl/Donepezil Hcl
Brand name: Namzaric
Rank #362 of 500 drugs by total cost
$27.2M
Total Cost
46,134
Total Claims
$27.2M
Total Cost
1,859
Prescribers
$589
Cost per Claim
1,583
Beneficiaries
54,815
30-Day Fills
$15K
Avg Cost/Provider
25
Avg Claims/Provider
About Memantine Hcl/Donepezil Hcl
Memantine Hcl/Donepezil Hcl (sold as Namzaric) was prescribed 46,134 times by 1,859 Medicare Part D providers in 2023, costing the program $27.2M. At $589 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 359 | Valsartan/Hydrochlorothiazide (Valsartan-Hydrochlorothiazide) | $27.5M | 510,583 |
| 360 | Ropinirole Hcl (Ropinirole Hcl) | $27.5M | 1,204,903 |
| 361 | Trifluridine/Tipiracil Hcl (Lonsurf) | $27.3M | 2,430 |
| 362 | Memantine Hcl/Donepezil Hcl (Namzaric) | $27.2M | 46,134 |
| 363 | Solifenacin Succinate (Solifenacin Succinate) | $27.1M | 343,174 |
| 364 | Insulin Aspart (Niacinamide) (Fiasp Flextouch) | $27.0M | 24,598 |
| 365 | Lisinopril/Hydrochlorothiazide (Lisinopril-Hydrochlorothiazide) | $26.8M | 2,304,445 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology